Market closed

Sight Sciences/$SGHT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Ticker

$SGHT
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Equipment & Supplies
Headquarters
Menlo Park, United States

Employees

214
Website
www.sightsciences.com

Sight Sciences Metrics

BasicAdvanced
$160M
-
-$1.01
2.73
-

$160M

2.73

$8.45

$3.15

221K

10.18

9.529

35.966

35.966

-8.69%

-19.40%

-45.36%

1.967

1.67

1.67

-6.042

-3.99%

-20.45%

22.51%

-32.42%

What the Analysts think about Sight Sciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.

Sight Sciences Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sight Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Sight Sciences News

AllArticlesVideos
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

GlobeNewsWire·4 weeks ago
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewsWire·2 months ago
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SGHT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sight Sciences stock?

Sight Sciences (SGHT) has a market cap of $160M as of January 15, 2025.

What is the P/E ratio for Sight Sciences stock?

The price to earnings (P/E) ratio for Sight Sciences (SGHT) stock is 0 as of January 15, 2025.

Does Sight Sciences stock pay dividends?

No, Sight Sciences (SGHT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Sight Sciences dividend payment date?

Sight Sciences (SGHT) stock does not pay dividends to its shareholders.

What is the beta indicator for Sight Sciences?

Sight Sciences (SGHT) has a beta rating of 2.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.